aTyr Pharma (NASDAQ:LIFE) Stock Upgrade
In a research note shared with investors on Wednesday morning, BidaskScore announced that they have decided to upgrade aTyr Pharma (NASDAQ:LIFE) shares to a “Sell”.
The stock decreased 0.75% or $0.0035 during the last trading session, reaching $0.4612. About 298,381 shares traded or 15.66% up from the average. aTyr Pharma, Inc. (NASDAQ:LIFE) has declined 84.92% since March 13, 2018 and is downtrending. It has underperformed by 89.29% the S&P500.
Analysts await aTyr Pharma, Inc. (NASDAQ:LIFE) to report earnings on March, 18. They expect $-0.19 earnings per share, up 51.28 % or $0.20 from last year’s $-0.39 per share. After $-0.24 actual earnings per share reported by aTyr Pharma, Inc. for the previous quarter, Wall Street now forecasts -20.83 % EPS growth.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $15.63 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.
More notable recent aTyr Pharma, Inc. (NASDAQ:LIFE) news were published by: Nasdaq.com which released: “‘El Chapo’ faces prison for life, but Mexico drug trade persists – Nasdaq” on February 12, 2019, also Nasdaq.com with their article: “Better Choice Company Announces Launch of 9 New CBD Product SKUs – Nasdaq” published on March 12, 2019, Nasdaq.com published: “Assurant (AIZ) Gains 15% in a Year: Will the Rally Continue? – Nasdaq” on March 07, 2019. More interesting news about aTyr Pharma, Inc. (NASDAQ:LIFE) were released by: Nasdaq.com and their article: “Roche’s (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer – Nasdaq” published on March 12, 2019 as well as Nasdaq.com‘s news article titled: “Why NOW Is the Time to Buy Gene Therapy Stocks – Nasdaq” with publication date: March 04, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.